Symbiotec Pharmalab Limited submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information to the Bombay Stock Exchange and National Stock Exchange on September 3, 2026.

The filing was made pursuant to Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The company stated that the code is framed under Regulation 8(1) of the same regulations.

Salil Jain, Company Secretary and Compliance Officer, signed the intimation letter addressed to the Listing Departments of both exchanges. The submission serves as an informational record for the exchanges.

Policy Effective Date

The policy shall come into effect on December 15, 2025. This retroactive effective date aligns the company’s internal compliance framework with prior regulatory expectations.

Fair Disclosure Principles

The code aims to preserve the confidentiality of unpublished price sensitive information (UPSI) and prevent its misuse. Key principles include:

• Promptly disclosing publicly any UPSI that would impact price discovery.
• Uniformly disseminating UPSI to avoid selective disclosure by communicating with stock exchanges and publishing on the company website.
• Disclosing press releases considered important for the general public.
• Publishing quarterly and annual financial results and investor presentations on the company website.
• Promptly disseminating UPSI disclosed selectively or inadvertently.
• Handling price sensitive information on a need-to-know basis.

Chief Investor Relations Officer

The Board of Directors has appointed a Chief Investor Relations Officer (CIRO), who reports to the Chief Financial Officer. The CIRO is responsible for compliance with the Fair Disclosure Code and handling dissemination of information. Employees are not authorized to respond to enquiries from stock exchanges or media unless approved by the CIRO or CFO.

Company Details

The registered office of Symbiotec Pharmalab Limited is located in Indore, Madhya Pradesh.

Mirae Asset Mutual Fund increased its stake in Symbiotec Pharmalab to 6.22% following an open market purchase of 34,97,420 shares on September 1, 2026. This acquisition represents a significant increase in the asset manager's exposure to the pharmaceutical company.

The transaction was disclosed under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Prior to this acquisition, Mirae Asset held 498,019 shares, representing 0.78% of the company's total share capital.

Acquisition Details

The fund acquired the additional shares through the open market mechanism. There were no warrants, convertible securities, or other instruments involved in this specific transaction. The acquisition did not involve any encumbrances such as pledges or liens.

Symbiotec Pharmalab's total equity share capital remained unchanged at 64,256,112 shares after the transaction. The total diluted share capital stands at 64,318,172 shares.

What the Numbers Show

The acquisition marks a substantial shift in institutional interest, with Mirae Asset increasing its position by more than eight times its previous holding. The jump from a sub-1% stake to over 6% indicates a decisive accumulation strategy by the mutual fund rather than incremental trading.